Abstract
Abstract Tumor cells constitutively express indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan and lowers tryptophan concentration in the local microenvironment. Such altered microenvironment protects tumor cells from rejection by the immune system, as T lymphocytes are exquisitely sensitive to tryptophan shortage. This may explain the low clinical efficacy of cancer immunotherapy based on vaccination. Preclinical studies indicate that this immune resistance mechanism can be blocked by systemic delivery of a pharmacological IDO inhibitor, 1-methyl- l -tryptophan. These results suggest the clinical efficacy of cancer immunotherapy can be boosted by combined treatment of cancer patients with an IDO inhibitor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
